Testosterone phenylpropionate

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Testosterone phenylpropionate

A mid-length testosterone ester, almost always used as one component of a blend such as Sustanon rather than on its own.

Evidence category: Reference only. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Testosterone phenylpropionate is a mid-length testosterone ester, hydrolysed to free testosterone after release from an intramuscular oil depot. It is one of four esters in Sustanon-type blends and has rarely been formulated or studied as a standalone injectable. Compiled clinical-pharmacology references (e.g. Wright & Burgess, Long Acting Injections and Implants, Springer 2012) describe a depot release lasting roughly eight days for this ester, but no dedicated single-compound human pharmacokinetic trial for phenylpropionate alone was located; the figure is a compiled reference value, not a primary study result.

Benefits reported in the imported source

• Contributes a mid-length release phase to blended esters such as Sustanon, between the fast propionate and the slow decanoate.

Risks and limits

• No dedicated single-compound human pharmacokinetic study exists; the release-duration figure comes from a compiled clinical-pharmacology reference, not a primary trial.
• Never marketed or studied as a standalone injectable.

Source bottom line: A mid-length testosterone ester known mainly as one component of blends such as Sustanon, with no dedicated human PK trial of its own.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

No community description recorded. This entry has no final B-82 outcome record; it is not a researched-empty finding.

Pharmacokinetic context

Historical half-life estimate: 192 hours. Compiled clinical-pharmacology reference (Wright & Burgess, Long Acting Injections and Implants, 2012) — depot release duration, not a dedicated single-compound PK trial Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Testosterone ester — Wikipedia overview
• Testosterone esters — Wikipedia overview